<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-OUXLTR5T</identifier><date>2021</date><creator>Eberl, Andreja</creator><relation>documents/doc/O/URN_NBN_SI_doc-OUXLTR5T_001.pdf</relation><relation>documents/doc/O/URN_NBN_SI_doc-OUXLTR5T_001.txt</relation><format format_type="issue">5</format><format format_type="volume">72</format><format format_type="type">article</format><format format_type="extent">str. 381-385</format><identifier identifier_type="ISSN">0014-8229</identifier><identifier identifier_type="COBISSID_HOST">88352003</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-OUXLTR5T</identifier><language>slv</language><publisher publisher_location="Ljubljana">Slovensko farmacevtsko društvo</publisher><source>Farmacevtski vestnik</source><rights>InC</rights><subject language_type_id="slv">ginekološki raki</subject><subject language_type_id="slv">interakcije med zdravili</subject><subject language_type_id="slv">neželeni učinki</subject><subject language_type_id="slv">protitumoena zdravilaž</subject><title>Cancer therapy in women (clinical cases)</title><title>Terapija rakavih obolenj pri ženskah (klinična primera)</title></Record>